Posted by Michael Wonder on 29 Sep 2021
FDA approves Qulipta (atogepant), the first and only oral CGRP receptor antagonist specifically developed for the preventive treatment of migraine
27 September 2021 - Qulipta demonstrated statistically significant, clinically meaningful rapid and continuous reductions in mean monthly migraine days among adults with episodic migraine compared to placebo across the 12 week treatment period with significant reductions seen in weeks 1-4.
AbbVie today announced that the U.S. FDA approved Qulipta (atogepant) for the preventive treatment of episodic migraine in adults.
